Onco Wiki / Disease

Pancreatic neuroendocrine tumor (pNET), well-differentiated G1/G2

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

IDDIS-PNET
TypeDisease
Aliases
Functional pNET (insulinoma, gastrinoma, glucagonoma, VIPoma)Non-functional pNETPancreatic islet cell tumorPancreatic neuroendocrine tumorpNETНейроендокринна пухлина підшлункової залози (пНЕП), добре-диференційована G1/G2
Statusreviewed 2026-05-03 | pending_clinical_signoff
DiseasesNone declared
SourcesSRC-NCCN-NET-2025

Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.

Source YAML

icd_o_3_morphology8240/3
icd_o_3_topography["C25"]
icd_10C25.4
who_classificationWHO Classification of Digestive System Tumours 5th ed (2019): Pancreatic neuroendocrine tumour G1 (Ki67 <3%), G2 (3–20%), G3 (>20% but well-differentiated)

Capabilities

Notes

Well-differentiated pNET G1/G2 is the dominant subtype in clinical practice (non-functional, discovered incidentally or via abdominal mass/liver mets). Grading per WHO 2019: G1 Ki67 <3%, G2 Ki67 3–20%. G3 well-differentiated pNET (Ki67 >20%) occupies a grey zone — still well-differentiated morphologically but higher proliferation; NCCN recommends everolimus/sunitinib/SSA ± chemo; not modelled separately here (flagged via RF-NET-HIGH-GRADE-G3 for MDT review). Distinguishing from poorly differentiated NEC (ICD-O 8246/3) is essential: NEC requires platinum-etoposide chemotherapy (not SSA/TKI/mTOR). Key trials: RADIANT-3 (everolimus, Yao NEJM 2011), Raymond 2011 (sunitinib), CLARINET pNET subgroup (lanreotide). Surgery remains the only curative option for localized disease.

Used By

Actionability

Algorithms

Disease

Indication

Procedures

Questionnaires

Red flag

Sources